What is claimed is:

1. A foamable pharmaceutical composition comprising:

a) halobetasol or its pharmaceutically acceptable salts, esters, and solvates;

b) an aliphatic alcohol;

c) at least one foam structuring agent comprising one or more fatty alcohols, non-ionic surfactants, or combinations thereof;

d) a polyol; and

e) water, wherein the composition is void of a buffer.

2. The composition of claim 1, wherein the halobetasol is halobetasol propionate.

3. The composition of claim 1, wherein the aliphatic alcohol is methyl, ethyl, isopropyl or butyl alcohol, or a combination thereof.

4. The composition of claim 1, wherein the fatty alcohol is selected from the group consisting of lauryl alcohol, myristyl alcohol, cetyl alcohol, lauryl alcohol, stearyl alcohol, octyldodecanol, and combinations thereof.

5. The composition of claim 1, wherein the polyol is selected from the group consisting of glycerin, propylene glycol, butylene glycol, dipropylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol and combinations thereof.

6. The composition of claim 1, wherein the at least one foam structuring agent comprises an ethoxylated alcohol.

7. The composition of claim 6, wherein the ethoxylated alcohol is polyoxyl 20 cetostearyl ether.

8. The composition of claim 1, wherein the at least one foam structuring agent is a combination of one or more of the following: cetyl alcohol, stearyl alcohol, and an ethoxylated alcohol.

9. The composition of claim 1, wherein the at least one foam structuring agent is Emulsifying Wax, NF.

10. The composition of claim 1, further comprising a can corrosion inhibitor, the inhibitor being less than approximately 0.005% w/w of benzoic acid.

11. The composition of claim 1, wherein the composition has a pH of about 4.0-6.3 or about 5.0-5.5.

12. The composition of claim 1, filled into a suitable canister and further comprising a propellant selected from propane, n-butane, isobutane, n-pentane, isopentane, dichloro difluoro methane, dichloro tetrafluoro ethane, octafluoro cyclobutane, 1,1,1,2-tetrafluoroethane, 1,1-difluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and mixtures of two or more thereof to produce a clear single-phase solution when canisters are charged with propellant.

13. The composition of claim 12, wherein the propellant level provides optimum quality of the foam and produces traditional rigid (mousse-like) and thermolabile (quick-break) characteristics.

14. The composition of claim 13, wherein the propellant comprises propane, n-butane, isobutane, or any combination thereof.

15. The composition any of claims 1-14, further comprising one or more members selected from the group consisting of: one or more additional therapeutic agents, coloring agents, preservatives, viscosity control agents, and fragrances.

16. The composition of any of claims 1-15, wherein the composition has an acceptable shelf-life of greater than about 24, 27, 30, 33, 36, 39, 42, 45, 48 months.

17. The composition of claim 16, wherein the shelf-life is determined at International Conference on Harmonisation (ICH) long-term storage condition by:

a) the 95% one-sided lower confidence interval of the linear regression of the assay for halobetasol or its pharmaceutically acceptable salts, esters, and solvates;

b) the 95% one-sided upper confidence interval of the linear regression of the degradant products for halobetasol or its pharmaceutically acceptable salts, esters, and solvates; or

c) the pH stability of the composition.

18. A storage stable, foamable composition comprising, on a weight basis:

a) 0.02 to 0.10% halobetasol or its pharmaceutically acceptable salts, esters, and solvates;

b) 40 to 60% ethyl alcohol;

c) 0.1 to 5.0% Emulsifying Wax, NF;

d) 0.05 to 1.0% cetostearyl alcohol;

e) 0.05 to 1.0% polyoxyl 20 cetostearyl ether;

f) 1 to 10% propylene glycol;

g) 30 to 40% water; and

h) less than 0.001% benzoic acid as a can corrosion inhibitor,

wherein the composition has a pH of between about 4.0 to 6.3.

19. The composition of claim 18, present in a suitable canister further comprising propane, n-butane, isobutane, and combinations thereof, at 3.25 to 5.75% w/w.

20. The composition of claim 19, wherein the propellant comprises 3.5 to 4% w/w.

21. The composition of claim 18, wherein the composition has an acceptable shelf-life of greater than about 24, 27, 30, 33, 36, 39, 42, 45, 48 months.

22. The composition of claim 21, wherein the shelf-life is determined at International Conference on Harmonisation (ICH) long-term storage condition by:

a) the 95% one-sided lower confidence interval of the linear regression of the assay for halobetasol or its pharmaceutically acceptable salts, esters, and solvates;

b) the 95% one-sided upper confidence interval of the linear regression of the degradant products for halobetasol or its pharmaceutically acceptable salts, esters, and solvates; or

c) the pH stability of the composition.

23. A composition of any claims 1-22, for treating a subject having, or at risk of having, a skin disease, condition or disorder, by topically administering the said composition to the subject in need thereof , thereby treating the skin disease, condition or disorder.

24. The composition of claim 23, wherein the skin disease, condition or disorder is a corticosteroid-responsive dermatosis.

25. The composition of claim23, wherein the administration does not decrease transepidermal water loss (TEWL) at the treated administration site and does not increase skin hydration at the treated administration site.